问题 › 我们的营销支出没有效果 › HealthTech与数字健康
大多数无效的营销支出，都是把钱花在无法触及签约会员或支付方的渠道上，而且衡量方式无法将支出与归因结果或风险分担挂钩。 对于数字健康公司，这个问题有特定表现。关键数字是风险收入分成和参与率，而这个行业的特殊复杂性在于，承担结果风险的速度快于公司验证自身能否承担该风险的速度——12个月的衡量窗口对11个月的销售周期。通用版本的问题与你实际面临的问题，初始应对措施不同。
大多数无效的营销支出，都是把钱花在无法触及签约会员或支付方的渠道上，而且衡量方式无法将支出与归因结果或风险分担挂钩。 对于数字健康公司，这个问题有特定表现。关键数字是风险收入分成和参与率，而这个行业的特殊复杂性在于，承担结果风险的速度快于公司验证自身能否承担该风险的速度——12个月的衡量窗口对11个月的销售周期。通用版本的问题与你实际面临的问题，初始应对措施不同。
两种不同的失败会产生同样的抱怨。渠道确实无法触及合同覆盖的人群，此时增加预算只会扩大风险收入分成的敞口。或者渠道能触及他们，但衡量系统无法将支出与参与率或客户流失关联起来，此时支出是用不匹配销售周期的窗口来评判的。
区分这两种情况首先是衡量问题。如果无法按渠道计算风险分成和PMPM，再多的创意或定向工作也无法解决争论，预算分配将取决于谁对毛利率影响最有信心。
第二个问题是回报而非规模。一个渠道获取成本高但能在衡量窗口内推动归因结果，就是可投入的；一个获取成本低但在窗口外产生流失的则不可，无论线索成本显示如何。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 无法按渠道说明风险分成或PMPM
✓ 支出用参与率或注册会员而非归因结果或客户流失来辩护
✓ 表现最佳的渠道会随CEO还是CFO汇报而变化
通常会让情况更糟的做法。 在修复风险分成的衡量前优化创意和定向，这会让一年内的决策都基于不可靠的数字。
It is for you if you run or finance a digital health company and cost per acquisition cannot be stated by channel. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market与商业策略, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
唯一有意义的检验是与生命周期价值和回本期对比，这两者都因业务而异。一种模式下优秀的成本，在相同收入的另一种模式下可能是致命的。
足够覆盖你的销售周期加上一个回本期，不能更长。过早判断会扼杀慢生效的渠道；过晚判断会持续资助永远不会奏效的渠道。
先削减无法衡量的渠道——风险集中在那里。统一削减会把有效渠道和无效渠道一起去掉。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית